Personalized Cancer Vaccine Market Size to be Worth USD 12.30 Billion by 2035; Increased Adoption of mRNA Vaccine Technology to Boost Industry Growth Globally | SNS Insider
Austin, May 18, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Personalized Cancer Vaccine Market was valued at USD 302 million in 2025 and is expected to reach USD 12.30 billion by 2035, growing at a CAGR of 44.88% over 2026–2035.
Market growth is attributed to increasing use of combination therapies involving personalized cancer vaccines used alongside immune checkpoint inhibitors like pembrolizumab and nivolumab. Scientific research has shown that such combination therapies lead to synergistic stimulation of the immune system that yields better results than using one approach alone.
Get a Sample Report of Personalized Cancer Vaccine Market Forecast @ https://www.snsinsider.com/sample-request/7652
The U.S. Personalized Cancer Vaccine Market was valued at USD 76.8 million in 2025 and is expected to reach USD 2.743 billion by 2035, registering a CAGR of 42.99% during 2026–2035.
The U.S. represents the country most technologically advanced in terms of personalized cancer vaccines and also commercial in its relevance owing to the large number of trials undertaken in the country. An extensive budget by the National Cancer Institute in research and development of the drug, which is expected to exceed USD 7.2 billion in 2024, and some of the most prominent personalized vaccine manufacturers globally, such as Moderna, Gritstone Bio, and Nouscom are boosting the market growth in the country.
The Europe Personalized Cancer Vaccine Market is estimated to be USD 84 Million in 2025 and is projected to reach USD 3.18 Billion by 2035, growing at a CAGR of 43.77% during 2026–2035.
The second-biggest regional market for personalized cancer vaccines is Europe, where there are effective collaborations between researchers within the European Cancer Organization and ECOG-ACRIN. The PRIME designation pathway at the European Medicines Agency has been used for Moderna and Merck’s mRNA-4157/V940 in metastatic melanoma.
High manufacturing complexity and cost Propel Market Growth Globally
One of the key limitations faced by the Personalized Cancer Vaccine Market is that of manufacturing complexity involved in producing vaccine constructs for each patient individually in a timely fashion. This includes tumor biopsy, whole exome sequencing, priority ranking of neoantigens through bioinformatics, conversion of sequence data into synthesis, formulation, quality control, and finally shipment to the clinical site, with all of these steps being potentially bottlenecks that could result in delay in initiation of therapy in a clinically meaningful manner.
Segmentation Analysis:
By Vaccine Type
Neoantigen vaccines were estimated to have a market share of nearly 48% of the Personalized Cancer Vaccines market in 2025 due to their intrinsic relevance to the precision oncology concept globally. mRNA-based vaccines represent both the fastest-growing segment as it is the most scalable manufacturing pathway for personalized cancer vaccines globally.
By Cancer Type
Melanoma retained the largest cancer type revenue share at approximately 26% of the Personalized Cancer Vaccine Market in 2025 as it is the lead indication for personalized cancer vaccine clinical development. Lung Cancer is projected to be the fastest-growing cancer type segment through 2035, driven by its extraordinary global incidence as the leading cause of cancer mortality globally.
For a Personalized Briefing with Our Industry Analysts, Connect Now @ https://www.snsinsider.com/request-analyst/7652
Regional Insights:
North America was the leading geographic market of the Global Personalized Cancer Vaccine Market in 2025, with over 85% of its income coming from the United States alone. The market dominance of the United States can be explained through its cutting-edge environment for cancer immunotherapy R&D and NCI funding for cancer studies.
The Asia-Pacific region is expected to register the highest regional CAGR until 2035 on the back of rising cancer incidence in China, India, Japan, and South Korea, rising investments by governments in precision and genomic medicine, and rising collaborations between academia and industries for cancer immunotherapy.
Major Players Analysis Listed in the Personalized Cancer Vaccine Market Report:
Recent Developments:
Purchase Single User PDF of Personalized Cancer Vaccine Market Report @ https://www.snsinsider.com/checkout/7652
Exclusive Sections of the Report (The USPs):
Personalized Cancer Vaccine Market Report Scope
Demand for Industry Analysis: Our Comprehensive Report Personalized Cancer Vaccine Market @ https://www.snsinsider.com/reports/personalized-cancer-vaccine-market-7652
Other Trending Related Report:
mRNA Therapeutics Market
mRNA Technology Market
Precision Oncology Market
Cancer Stem Cells Market
Tumor Profiling Market
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.